Boldly de-risking development of impactful cell and gene therapies: the California Stem Cell Agency’s $3B funding model

Published: 5 October 2020
Commentary
Shyam Patel,
Shyam Patel
Associate Director, Portfolio Development & Review at California Institute For Regenerative Medicine
Sohel Talib,
Sohel Talib
Director, Therapeutics at California Institute For Regenerative Medicine
Maria Millan
Maria Millan
Vice President, Therapeutics at California Institute For Regenerative Medicine

The California Institute for Regenerative Medicine (CIRM) is California’s Stem Cell funding agency [1]. Since its inception in 2004, CIRM has deployed $2.7B to advance development of stem-cell based regenerative medicine therapies for patients with unmet medical needs. This perspective highlights 3 elements of CIRM’s funding model that have enabled California academic researchers and companies to de-risk development of novel regenerative medicine therapies and attract biopharma industry support. To date, CIRM has funded over 1000 projects including 64 regenerative medicine clinical trials; over half the clinical trial projects have secured biopharma industry support. Overall, CIRM funding has enabled the launch of 44 companies and CIRM-funded projects have drawn in a cumulative $9B in industry investments.

Read now